Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.46 |
| ▸ | HTR2C | P28335 | 2/20 | 0.46 |
| ▸ | HTR2B | P41595 | 2/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | APEX1 | P27695 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
| ▸ | NEK2 | P51955 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10232753 | 0.77 | TOP2A (0.32) | CRBNTDP1SIGMAR1 | |
| SCHEMBL7881654 | 0.77 | DRD2 (0.42) | DRD2CRBN | |
| SCHEMBL1350944 | 0.77 | HTR2A (0.50) | HTR2AHTR2CHTR2BDRD2KDM4E | |
| SCHEMBL2013376 | 0.74 | DRD2 (0.48) | HTR2AHTR2CHTR2BDRD2KDM4E | |
| SCHEMBL2014167 | 0.74 | DRD2 (0.48) | HTR2AHTR2CHTR2BDRD2KDM4E | |
| SCHEMBL25039621 | 0.73 | HTR2A (0.41) | HTR2AHTR2CHTR2BDRD2KDM4E | |
| SCHEMBL21739442 | 0.73 | HTR2A (0.41) | HTR2AHTR2CHTR2BDRD2KDM4E | |
| SCHEMBL21740351 | 0.73 | HTR2A (0.41) | HTR2AHTR2CHTR2BDRD2KDM4E | |
| SCHEMBL2558862 | 0.73 | HTR2C (0.45) | HTR2AHTR2CHTR2BDRD2 | |
| SCHEMBL692247 | 0.73 | HTR2C (0.45) | HTR2AHTR2CHTR2BDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-05-10 | — | — | US | disclosed |
| WO-2010118207-A1 | PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS | SCHERING CORPORATION (US) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MTOR, RICTOR, RPTOR | HTR2A 2788/4885HTR2C 2963/4885HTR2B 3731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.